Efficacy and safety of amlodipine: A comparative study of hypertensive patients treated at primary-and specialised-care centres

Clinical Drug Investigation

Volumn 26, Issue 3, 2006, Pages 125-133

  Valcarcel Y ^a   Jimenez R ^a   Hernandez V ^a   Aristegui R ^b   Gil, A ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIASTOLE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; SYSTOLE;

ADULT; AGED; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; DIASTOLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SYSTOLE;

EID: 34548532265     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/00044011-200626030-00002     Document Type: Article

References (47)

1. Arístegui I, Calderón A, Gómez de la Cámara J, et al. Reducción del riesgo en la hipertensión arterial asociada a factores de riesgo cardiovascular. Proyecto HYDRA. Hipertensión 2000; 17 (3): 31-42
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413-46
3. Wilson PKW. Hypertension, other risk factors and the risk of cardiovascular disease. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1995: 99-114
4. Cupples L, D'Agostino R. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennale measurements: Framingham Heart Study, 30-year follow-up. In: Kannel WB, Wolf PA, Garrison RJ, editors. The Framingham Study: an epidemiological investigation of cardiovascular disease. Washington: US Department of Health, Education and Welfare; 1987 [Cat no. NIH 87-2284]
5. Banegas JR, Rodríguez-Artalejo F, de la Cruz Troca JJ, et al. Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension. 1998; 32 (6): 998-1002
6. Abellán J, Leal M. Importancia sociosanitaria de la hipertensión. In: Ediciones DOYMA. Epidemiología de la hiperten-sión. Madrid: Biblioteca básica SEH-LELHA, 1999
7. Ministerio de Sanidad y Consumo, Consenso para el control de la hipertensión en España; 1990
8. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-71
9. Hypertension Control. Report of a WHO Expert Committee 49. Geneva: World Health Organization (WHO Technical Report Series, No. 862), 1996
10. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319 (7210): 630-5
11. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 1999; 161 Suppl. 12: S1-17
12. Sociedad Española de Hipertensión-Liga Española para la lucha contra la Hipertensión (SEH-LELHA). Importancia de la Hipertensión Arterial Sistólica. Madrid: SEH-LELHA; 2001
13. Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España. Hipertensión 2002; 19 (3)
14. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. Hiperten-sión 2002; 19 (9): 390-9
15. Grupos de Trabajo en Hipertensión. Observancia terapéutica en el paciente hipertenso. Madrid: Sociedad Española de Hipertensión, 1996
16. Puras A, Sanchís C. El control de la hipertensión arterial en España: el objetivo más importante pero más olvidado de los últimos años. Med Clín (Barc) 1997; 108: 734-6
17. Banegas JR, Rodríguez F, Cruz JJ, et al. Blood pressure in Spain: distribution, awareness, control and benefits of a reduction in average pressure. Hypertension 1998; 32: 998-1002
18. Malacco E, Leonetti G, Santini F. Comparison of calcium antagonist and an ACE inhibitor in the treatment of elderly hypertensive patients. Curr Ther Res 1993; 54: 695-702
19. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50 (3): 560-86
20. Chrysant SG, Chrysant C, Trus J, et al. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothia-zide. Am J Hypertens 1989; 2 (7): 537-41
21. Ghorayeb N, Armaganijan D, Neto F. Effects of amlodipine on mild to moderate arterial hypertension in elderly patients: long-term study. Revista Brasileira de Medicina 1994; 51 (8): 1061-4
22. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17 (2): 151-83
23. The ALLHAT officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288 (23): 2981-97
24. Gil A, Jiménez R, San Martín M, et al. Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON Study. Current Therapeutic Research 2000; 61 (12): 863-70
25. Anegón M, Esteban J, Jiménez-García R, et al. Estudio de farmacovigilancia para evaluar la seguridad y efectividad de doxazosina GITS en pacientes hipertensos que recibiían tratamiento previo con doxazosina estándar. Hipertensión 2001; 18: 411-7
26. Kaplan NM. The CARE Study: a postmarketing evaluation of ramipril in 11, 100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther 1996; 18 (4): 658-70
27. Osterloh I. The safety of amlodipine. Am Heart J 1989; 118 (5 Pt 2): 1114-9
28. Pessina A, Galluci M. Assessment and tolerability and efficacy of amlodipine in 9294 patients with mild or moderate essential hypertension. Clin Drug Invest 1997; 13 (1): 137-42
29. Ram CV, Ames RP, Applegate WB, et al. Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Clin Cardiol 1994; 17 (5): 251-6
30. Kubota K, Pearce GL, Inman WHW. Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring. Eur J Clin Pharmacol 1995; 48: 1-7
31. Julius S. Amlodipine in hypertension: an overview of the clinical dossier. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: S27-33
32. Cross BW, Kirby MG, Miller S, et al. A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension. Br J Clin Pract 1993; 47 (5): 237-40
33. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 98. Hipertensión 2000; 15: 298-307
34. Prieto M, De Abajo FJ, Montero D, et al. Uso de antihipertensivos en España 1985-1995 65. Medicina Clínica 1998; 110: 247-53
35. Aranda P, Tamargo J, Aranda FJ, et al. Uso y reacciones adversas de los antihipertensivos en España. Estudio RAAE (I Parte). Hipertensión 1996; 13 (25): 35
36. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudo Controlpres 2001. Hipertensión 2002; 19 (9): 390-9
37. Tranche S, Marín R, Prieto MA, et al. La presión de pulso como marcador de riesgo cardiovascular. Hipertensión 2001; 18: 218-24
38. Cuspidi C, Lonati L, Sampieri L, et al. Blood pressure control in a hypertension hospital clinic. J Hypertens 1999; 17 (6): 835-41
39. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40 (4): 464-9
40. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40 (4): 464-9
41. Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43 (6): 1338-44
42. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 [published erratum in Hypertension 1996; 27 (5): 1192]. Hypertension 1995; 26 (1): 60-9
43. Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid? J Hum Hypertens 1997; 11 (4): 213-20
44. Mancia G, Sega R, Milesi C, et al. Blood-pressure control in the hypertensive population. Lancet 1997; 349 (9050): 454-7
45. Banegas J, Rodríguez-Artalejo F, De la Cruz J, et al. Blood pressure in Spain. Distribution, awareness, control and benefits of a reduction in average blood pressure. Hypertension 1998; 32: 988-1002
46. Banegas J, Rodríguez-Artalejo F, Ruilope L, et al. Hypertension magnitude and management in the elderly population of Spain. J Hypertens 2002; 20: 2157-64
47. Felip A, Davins J, Poch E, et al. Indicadores de calidad en las unidades asistenciales de hipertensión arterial: indicadores de estructura [abstract]. Revista de la Sociedad Española de Hipertensión 2005, 289